m 6 A‐Mediated Glycolysis by IL‐37 Drives T Cell Metabolic Reprogramming to Regulate Colitis
Advanced Science · 2026
DOI: 10.1002/advs.202520472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Xiaoyan Wang und 26 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Ch…. Hauptthemen laut MEDLINE: Colitis, Interleukin-1, Adenosine, Glycolysis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
N6‐methyladenosine (m 6 A) modification and T‐cell metabolic reprogramming are increasingly recognized as critical drivers of inflammatory bowel disease (IBD). However, how the anti‐inflammatory cytokine interleukin‐37 intersects with m 6 A‐mediated metabolic regulation remains unclear. Here, we show that IL‐37 alleviates colitis by reducing global m 6 A levels and reshaping CD4 + T‐cell metabolism. Mechanistically, IL‐37 signals through its receptor SIGIRR to inhibit IRAK4 and JNK phosphorylation, suppress NF‐κB p65 activation, and downregulate METTL14, thereby decreasing m 6 A deposition. The IL‐37/METTL14 axis notably reduces m 6 A enrichment at the A2445 site in the 3′UTR of SLC2A1, destabilizing its mRNA and suppressing glycolysis. In vitro T‐cell polarization and adoptive transfer of METTL14‐overexpressing CD4 + T cells confirmed that this metabolic shift restrains Th1/Th17 differentiation while promoting Th2 expansion. Together, these findings reveal the IL‐37/SIGIRR–METTL14–m 6 A axis as a novel regulator of T‐cell metabolism and highlight SLC2A1 as a potential therapeutic target in IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, China.
- Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- CDUTCM-KEELE Joint Health and Medical Sciences Institute, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
ORCID-Profile: Jiong Li
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, X., Yu, J., Li, G., Li, Y., Zeng, F., Hu, J., Zhou, Y., Yue, C., Zhao, Q., Zhang, C., Zhou, H., Zhao, F., Hu, Y., Zhou, P., Gu, L., Feng, Y., He, M., Huang, S., Sun, X., …, & Li, J. (2026). m 6 A‐Mediated Glycolysis by IL‐37 Drives T Cell Metabolic Reprogramming to Regulate Colitis. Advanced Science. https://doi.org/10.1002/advs.202520472
Vancouver
Wang X, Yu J, Li G, Li Y, Zeng F, Hu J, et al. m 6 A‐Mediated Glycolysis by IL‐37 Drives T Cell Metabolic Reprogramming to Regulate Colitis. Advanced Science. 2026. doi:10.1002/advs.202520472
BibTeX
@article{Wang2026,
author = {Wang, Xiaoyan and Yu, Jiadong and Li, Guolin and Li, Ya and Zeng, Fanlian and Hu, Jing and Zhou, Yifan and Yue, Chengcheng and Zhao, Qixiang and Zhang, Chen and Zhou, Hong and Zhao, Fulei and Hu, Yawen and Zhou, Pei and Gu, Linna and Feng, Yuting and He, Mingxiang and Huang, Shishi and Sun, Xiaochi and Wang, Xinmeng and Tang, Jie and Zeng, Xinyu and Wu, Wenling and Huang, Nongyu and Cui, Xinai and Cui, Kaijun and Li, Jiong},
title = {m 6 A‐Mediated Glycolysis by IL‐37 Drives T Cell Metabolic Reprogramming to Regulate Colitis},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202520472}
}
EUVIMED